

1614

CEDAR-45257 (18810-80090)

Date Mailed: May 28, 2002

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

JUN 11 2002



TECH CENTER 1600/2901


#9
6-18-02
p. 7.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Anthony P. Heaney, Gregory A. Horwitz, Xun Zhang, and
Shlomo Melmed
Serial No. 09/730,469
Filed: December 4, 2000
For: METHODS OF USING PITUITARY TUMOR TRANSFORMING
GENE (PTTG) CARBOXY-TERMINAL PEPTIDES TO INHIBIT
NEOPLASTIC CELLULAR PROLIFERATION AND/OR
TRANSFORMATION OF BREAST AND OVARIAN CELLS
Examiner: Unknown
Unit: 1614

Assistant Commissioner for Patents
Washington, D. C. 20231

Dear Sir:

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS	
WASHINGTON, D. C. 20231, ON	MAY 28, 2002
BY 	ANN WEISS
	MAY 28, 2002 (DATE OF SIGNATURE)

Applicant's attorney submits herewith Form PTO-1449,
"Information Disclosure Statement" by Applicant referencing patents and/or
other literature of which he is aware, that he believes may be material to the
examination of this application and in respect of which there may be a duty to
disclose in accordance with 37 C.F.R. § 1.56.

A copy of each of the disclosed patent documents and other
references listed as other documents Nos. 64-65 are not being submitted
herewith, because under Rule 37 C.F.R. § 1.98(d) this art was previously cited
by the Examiner and/or the Applicant in connection with related application U.S.
Serial No. 09/569,956, filed May 12, 2000. This previously filed Application was
cited by applicant in this present Application per 35 U.S.C. § 120.

Date Mailed: May 28, 2002

The filing of this Supplemental Information Disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists (37 C.F.R. 1.97(h)). Further the filing of this Supplemental Information Disclosure statement shall not be construed as an admission against interest in any manner.

It is believed that this Supplemental Information Disclosure statement is being filed before the mailing of a first office action on the merits. However, the Commissioner is hereby authorized to credit overpayments or charge any fees required under 37 C.F.R. 1.16 or C.F.R. 1.17 to Deposit Account No. 50-1597.

Respectfully submitted,

By: 

Nisan A. Steinberg, Ph.D.
Registration No. 40,345

SIDLEY AUSTIN BROWN & WOOD LLP
555 West Fifth Street
Los Angeles, California 90013-1010
Ofc: 213/ 896-6665
Fax: 213/896-6600